Irinotecan (CPT-11)治療卵巢癌之檢視

Using Irinotecan in Patients with Epithelial Ovarian Cancer

李耀泰(Yiu-Tai Li) ； 陳福民(Fu-Min Chen) ； 柯天龍(Tien-Lung Ko) ； 鄭文雄(Wen-Hsiung Chen) ； 郭宗正(Tsung-Cheng Kuo)

《中華民國婦癌醫學雜誌》 2008年1期 (2008/04) Pp. 14-19

https://doi.org/10.7010/JGO.200804.0014

摘要

晚期卵巢癌的標準治療方法是先以減積手術盡量切除病灶，再給予carboplatin和paclitaxel做輔助化學治療。但大部份患者都會稪發，因此必需尋求第二線的化學藥物來再治療。Ininotecan (CPT-11)乃一種由植物鹼camptothecin來源之半合成產品，爲一很強的DNA topoisomerase I抑制劑，最初證明對大腸直腸癌有效。最近又證明對子宮頸癌和對platinum有抗藥性之卵巢癌有良好療效。

關鍵字

Irinotecan ； 卵巢癌

並列摘要

The standard initial combination chemotherapy after cytoreductive surgery for advanced ovarian cancer includes carboplatin and paclitaxel. However, more than half of patients will relapse and second-line agents are needed. Irinotecan (CPT-11) is a semisynthetic derivative of camptothecin and a potent inhibitor of DNA topoisomerase I, with demonstrated activity in colorectal cancer. It has recently been exhibited excellent antitumor activity in both cervical cancer and platinum-resistant ovarian cancer. In addition, several studies showed that the combination of irinotecan-mitomycin appeared to be useful and safe in patients with epithelial ovarian carcinoma. This review will focus on the role of irinotecan in epithelial ovarian carcinoma.

並列關鍵字

Irinotecan ； ovarian cancer